Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse
J. Clin. Invest. Nilamadhab Mishra, et al. 111:539 doi:10.1172/JCI16153 [Go to this article.]

Figure 7
Spleen weights of MRL-lpr/lpr mice receiving daily injections of either TSA (0.5 mg/kg BW in DMSO) or vehicle (DMSO) for 5 weeks beginning at 14 weeks of age (n = 5, P < 0.05).